Cabaletta Bio, Inc. CABA

US Biotechnology

$1.45 ▼ -3.33% ($-0.05)

🔥 High Short Interest 🎢 High Beta

Open $1.49

Prev Close $1.50

Day Range $1.41 – $1.54

52W Range $1.18 – $4.23

Market Cap $323.58M

Beta 3.82

EPS (TTM) $-1.57

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2019-10-25
Shares Out.	169,550,000
Website	cabalettabio.com ↗
Phone	13026587581
Employees	158
Revenue	$0
Gross Profit	$0
Net Income	-$53.1M
Free Cash Flow	-$162.5M
Total Assets	$336.5M
Total Liabilities	$52.6M
Equity	$283.9M

About Cabaletta Bio, Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Cabaletta Bio, Inc. is a publicly traded company under the ticker symbol CABA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.